Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $25.1875.

Several research analysts recently issued reports on ROIV shares. Leerink Partners lifted their target price on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. The Goldman Sachs Group raised their target price on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Guggenheim restated a “buy” rating and set a $28.00 price target on shares of Roivant Sciences in a research note on Thursday, December 18th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, JPMorgan Chase & Co. boosted their target price on Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 18th.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 75,000 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $22.53, for a total transaction of $1,689,750.00. Following the sale, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at approximately $37,278,070.41. The trade was a 4.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $23.07, for a total transaction of $17,933,049.24. Following the transaction, the director owned 16,353,113 shares of the company’s stock, valued at $377,266,316.91. The trade was a 4.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 13,004,502 shares of company stock worth $276,813,961. Corporate insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

A number of large investors have recently added to or reduced their stakes in ROIV. Bessemer Group Inc. raised its stake in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the period. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the last quarter. Utah Retirement Systems grew its holdings in shares of Roivant Sciences by 3.0% in the third quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock valued at $312,000 after purchasing an additional 600 shares in the last quarter. Xponance Inc. grew its stake in shares of Roivant Sciences by 1.9% in the 3rd quarter. Xponance Inc. now owns 46,718 shares of the company’s stock worth $707,000 after buying an additional 882 shares in the last quarter. Finally, CWM LLC increased its stake in Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after acquiring an additional 920 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Up 0.9%

Shares of ROIV stock opened at $21.98 on Monday. Roivant Sciences has a 52 week low of $8.73 and a 52 week high of $23.47. The company has a market cap of $15.29 billion, a price-to-earnings ratio of -39.25 and a beta of 1.22. The firm has a 50 day moving average of $21.21 and a 200-day moving average of $16.18.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.